KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 18.91%.

  • Sarepta Therapeutics' EBIT Margin rose 191100.0% to 18.91% in Q2 2025 from the same period last year, while for Jun 2025 it was 16.16%, marking a year-over-year increase of 136400.0%. This contributed to the annual value of 11.47% for FY2024, which is 330100.0% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported EBIT Margin of 18.91% as of Q2 2025, which was up 191100.0% from 24.56% recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' EBIT Margin ranged from a high of 24.56% in Q4 2024 and a low of 103.36% during Q1 2021
  • Moreover, its 5-year median value for EBIT Margin was 41.21% (2022), whereas its average is 32.67%.
  • As far as peak fluctuations go, Sarepta Therapeutics' EBIT Margin soared by 770400bps in 2021, and later crashed by -388500bps in 2022.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' EBIT Margin stood at 52.52% in 2021, then grew by 21bps to 41.34% in 2022, then skyrocketed by 115bps to 6.21% in 2023, then skyrocketed by 296bps to 24.56% in 2024, then decreased by -23bps to 18.91% in 2025.
  • Its EBIT Margin stands at 18.91% for Q2 2025, versus 24.56% for Q4 2024 and 4.75% for Q3 2024.